PALISADE BIO, INC.: Soleus Capital Master Fund, L.P. amends Schedule 13G stake filing
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
Soleus Capital Master Fund, L.P. amended its Schedule 13G stake filing for Palisade Bio, Inc., disclosing the change to the SEC under accession number 0001213900-26-117542. The filing updates the fund's reported ownership position in the clinical-stage biopharmaceutical company. Schedule 13G amendments are typically filed by passive investors when their holdings cross or adjust relative to the 5% threshold. The specific share count and percentage were not detailed in the filing summary. Investors will watch for further 13G or 13D activity to gauge Soleus's conviction in Palisade Bio.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.
Named in this story
Palisade Bio, Inc., Soleus Capital Master Fund, L.P.